



165 – 10551 Shellbridge Way  
Richmond, BC, V6X 2W8

## **BIOMARK SECURES DTC ELIGIBILITY**

Vancouver, British Columbia – (May 28, 2015) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B) (OTCQB: BMKDF) is pleased to announce that it has secured The Depository Trust Company (DTC) eligibility for its shares traded in the United States under the symbol BMKDF.

"DTC eligibility allows BioMark to significantly expand its U.S. and international shareholder base, increases the efficiency, and lowers the cost associated of trading BioMark stock in the US," said Rashid Ahmed, President and CEO of BioMark Diagnostics Inc.. "Securing DTC eligibility reflects our ongoing efforts to support our growing investor base in the U.S. who can now purchase and trade the securities more efficiently through their brokers."

BioMark will continue to trade on the Canadian Stock Exchange under its existing symbol BUX.

### **About DTC**

The DTC is a subsidiary of the Depository Trust & Clearing Corporation and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered "DTC eligible." This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors and brokers. Securities that are not DTC-eligible are often not accepted for trading at many brokerages due to the amount of paperwork and manpower required to execute and settle trades, thus making it more difficult for a significant percentage of investors to access the shares. Additionally companies that are approved for DTC electronic transfers often experience higher trading volumes in their stock given the additional accessibility and availability of shares for trading.

### **About BioMark Diagnostics Inc.**

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer, early and cost effectively. BioMark is currently conducting Multi site clinical trial for lung, breast, gastro intestinal and prostate cancers. Additionally trials related to assess response to lung cancer treatment and surgical interventions are being established.

Further information about BioMark is available under its profile on the SEDAR website [www.sedar.com](http://www.sedar.com) and on the CSE website [www.thecse.ca](http://www.thecse.ca).

**For further information on BioMark, please Contact:**

Rashid Ahmed Bux  
President & CEO  
BioMark Diagnostics Inc.  
Tel. 604-282-6567  
Email: [info@biomarkdiagnostics.com](mailto:info@biomarkdiagnostics.com)

**Forward-Looking Information:**

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

**The CSE has not reviewed, approved or disapproved the content of this press release.**